Lee, I.-C.; Chao, Y.; Lee, P.-C.; Chen, S.-C.; Chi, C.-T.; Wu, C.-J.; Wu, K.-C.; Hou, M.-C.; Huang, Y.-H.
Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers 2022, 14, 2014.
https://doi.org/10.3390/cancers14082014
AMA Style
Lee I-C, Chao Y, Lee P-C, Chen S-C, Chi C-T, Wu C-J, Wu K-C, Hou M-C, Huang Y-H.
Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers. 2022; 14(8):2014.
https://doi.org/10.3390/cancers14082014
Chicago/Turabian Style
Lee, I-Cheng, Yee Chao, Pei-Chang Lee, San-Chi Chen, Chen-Ta Chi, Chi-Jung Wu, Kuo-Cheng Wu, Ming-Chih Hou, and Yi-Hsiang Huang.
2022. "Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma" Cancers 14, no. 8: 2014.
https://doi.org/10.3390/cancers14082014
APA Style
Lee, I.-C., Chao, Y., Lee, P.-C., Chen, S.-C., Chi, C.-T., Wu, C.-J., Wu, K.-C., Hou, M.-C., & Huang, Y.-H.
(2022). Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers, 14(8), 2014.
https://doi.org/10.3390/cancers14082014